Pipeline of new drugs to fight superbugs is ‘worryingly thin’, experts warn

UK’s GSK is leading the way in research but AstraZeneca is not involved in the area, report finds Business live – latest updates The pipeline of drugs to fight superbugs remains “worryingly thin” and has shrunk by 35% in the last five years, experts have warned, predicting the annual number of deaths linked to drug-resistant infections globally will double to 8 million by 2050. The number of projects from large pharma companies has shrunk by 35% over the past five years, from 92 to 60 medic...

By Julia Kollewe